Skip to main content
Biomind Labs logo

Biomind Labs — Investor Relations & Filings

Ticker · BMND ISIN · CA0907021012 LEI · 254900YBPPG0XSZOE887 NEO Professional, scientific and technical activities
Open in API
Filings indexed 274 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CA Canada
Listing NEO BMND

About Biomind Labs

https://www.biomindlabs.com/

Biomind Labs is a biotechnology research and development company focused on creating novel pharmaceutical drugs for patients suffering from neurological and psychiatric disorders. The company employs an R&D acceleration platform to develop next-generation formulations, including those based on key endogenous substances. A core technological focus is the integration of nanotech delivery systems to target the underlying drivers of disease.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 82% confidence The document is a Form 52-109F2 CEO certification of interim filings under Canadian NI 52-109, attesting to review, fair presentation, DC&P and ICFR design. It contains no substantive financial statements or analysis and is purely an officer attestation. Under the Certification Rule, such attestations are classified as Regulatory Filings (RNS), not as an Interim Report or MD&A.
2026-05-15 English
Interim MD&A - English.pdf
Management Reports Classification · 97% confidence The document is titled “Management’s Discussion and Analysis for the three month period ended March 31, 2026” and contains forward‐looking statements, business overview, risks, program descriptions, and commentary on interim financial results. It refers to but does not include actual financial statements, and is clearly a standalone MD&A that accompanies interim reporting. Under our taxonomy, this falls under Management Reports (Code: MDA), which covers management’s detailed explanation of financial results, business trends and outlook.
2026-05-15 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled “Condensed Interim Consolidated Financial Statements” and covers the three-month period ended March 31, 2026 (unaudited, prepared under IFRS IAS 34). It includes actual financial statements (balance sheet, income statement, cash flows, notes) for a quarterly period. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a landmark executive order accelerating psychedelic research and access in the United States, highlighting the company's clinical trial results and strategic positioning. It contains no financial statements, detailed financial performance data, or regulatory filings. It is not an earnings release, annual report, or interim report. It is a corporate announcement focused on regulatory and strategic developments, not a report or detailed presentation. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing and applauding a landmark executive order by the U.S. President to accelerate psychedelic research and access. It discusses the regulatory environment, clinical trial results, company strategy, and forward-looking statements. There are no financial statements, detailed financial performance data, nor is this a transcript of a call or a regulatory filing with compliance certifications. The document is a corporate announcement about regulatory and policy developments impacting the company and its sector, not a formal report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, director dealing, or capital update. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and corporate news that does not fit other specific categories.
2026-04-20 English
Annual information form - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Information Form' for the year ended December 31, 2025, dated March 31, 2026. It contains detailed sections such as corporate structure, business description, risk factors, dividends, capital structure, directors and officers, legal proceedings, audit committee, and governance practices. The content is comprehensive and includes forward-looking statements, risk disclosures, and detailed corporate information. This type of document is typical of an Annual Information Form (AIF), which is a regulatory filing used primarily in Canada to provide detailed annual information about a company, supplementing the annual report but distinct from the 10-K. Given the detailed nature and length (15,000 characters), it is not a brief announcement or a proxy statement. It is not a financial statement report like a 10-K or IR, but rather a comprehensive annual disclosure document. The best fitting category from the provided list is Regulatory Filings (RNS) because the AIF is a regulatory filing that does not fit the other specific categories like 10-K or IR. The AIF is a Canadian regulatory filing and is not classified as a 10-K (which is a US SEC annual report). Therefore, the classification is RNS with high confidence.
2026-04-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.